Sorbera, L. A. published the artcileIndiplon: Treatment of insomnia GABA-A agonist, Category: amides-buliding-blocks, the publication is Drugs of the Future (2003), 28(8), 739-746, database is CAplus.
Six different synthetic routes are investigated for the preparation of N-Methyl-N-[3-[3-[2-thienylcarbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]a cetamide (Indiplon) and its potential use as a drug for treatment of insomnia is evaluated. Indiplon is a GABA-A receptor partial agonist that promotes sleep by enhancing the inhibitory activity of GABA through specific binding to the BZ1 or α1 subunit of the GABA-A receptor. Indiplon has been shown to be safe and well tolerated and is currently being developed in two formulations to treat all insomnia complaints, including sleep initiation, night awakenings and total sleep maintenance.
Drugs of the Future published new progress about 325715-13-7. 325715-13-7 belongs to amides-buliding-blocks, auxiliary class Amine,Benzene,Ketone,Amide, name is N-(3-Acetylphenyl)-N-methylacetamide, and the molecular formula is C12H10O4S, Category: amides-buliding-blocks.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics